Meningococcal serogroups and surveillance: a systematic review and survey

Background: Meningococcal disease continues to be a global public health concern due to its epidemic potential, severity, and sequelae. The global epidemiological data on circulating meningococcal serogroups have never been reviewed concurrently with the laboratory capacity for meningococcal surveil...

Descripción completa

Detalles Bibliográficos
Autores: Peterson, Meagan E, Li, You, Bita, André, Moureau, Annick, Nair, Harish, Kyaw, Moe H, Abad, Raquel, Bailey, Freddie, de la Fuente Garcia, Isabel, Decheva, Antoaneta, Krizova, Pavla, Melillo, Tanya, Skoczyńska, Anna, Vladimirova, Nadezhda
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/7530
Acceso en línea:http://hdl.handle.net/20.500.12105/7530
Access Level:acceso abierto
Palabra clave:Global Health
Humans
Meningococcal Infections
Meningococcal Vaccines
Neisseria meningitidis
Serogroup
id ES_afb02a80972cfaf9a2f8d4b08ae2b5ce
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/7530
network_acronym_str ES
network_name_str España
repository_id_str
spelling Meningococcal serogroups and surveillance: a systematic review and surveyPeterson, Meagan ELi, YouBita, AndréMoureau, AnnickNair, HarishKyaw, Moe HAbad, RaquelBailey, Freddiede la Fuente Garcia, IsabelDecheva, AntoanetaKrizova, PavlaMelillo, TanyaSkoczyńska, AnnaVladimirova, NadezhdaGlobal HealthHumansMeningococcal InfectionsMeningococcal VaccinesNeisseria meningitidisSerogroupBackground: Meningococcal disease continues to be a global public health concern due to its epidemic potential, severity, and sequelae. The global epidemiological data on circulating meningococcal serogroups have never been reviewed concurrently with the laboratory capacity for meningococcal surveillance at the national level. We, therefore, aimed to conduct a country-level review of meningococcal surveillance, serogroup distribution, and vaccine use. Methods: We conducted a systematic literature review across six databases to identify studies (published January 1, 2010 to October 16, 2017) and grey literature reporting meningococcal serogroup data for the years 2010-2016. We performed independent random effects meta-analyses for serogroups A, B, C, W, X, Y, and other. We developed and circulated a questionnaire-based survey to surveillance focal points in countries (N = 95) with known regional bacterial meningitis surveillance programs to assess their surveillance capacity and summarized using descriptive methods. Results: We included 173 studies from 59 countries in the final analysis. The distribution of meningococcal serogroups differed markedly between countries and regions. Meningococcal serogroups C and W accounted for substantial proportions of meningococcal disease in most of Africa and Latin America. Serogroup B was the predominant cause of meningococcal disease in many locations in Europe, the Americas, and the Western Pacific. Serogroup Y also caused many cases of meningococcal disease in these regions, particularly in Nordic countries. Survey responses were received from 51 countries. All countries reported the ability to confirm the pathogen in-country, while approximately 30% either relied on reference laboratories for serogrouping (N = 10) or did not serogroup specimens (N = 5). Approximately half of countries did not utilize active laboratory-based surveillance system (N = 22). Nationwide use of a meningococcal vaccine varied, but most countries (N = 36) utilized a meningococcal vaccine at least for certain high-risk population groups, in private care, or during outbreaks. Conclusions: Due to the large geographical variations in circulating meningococcal serogroups, each country should continue to be monitored for changes in major disease-causing serogroups in order to inform vaccine and control policies. Similarly, laboratory capacity should be appropriately scaled up to more accurately understand local epidemiology and disease burden, as well as the impact of vaccination programs.Edinburgh University PressThe China Scholarship CouncileSanofiInstitut Pasteur20192019-04-2920192019-06-0120192019-06-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/7530reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución-NoComercial-CompartirIgual 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/75302026-06-12T12:43:37Z
dc.title.none.fl_str_mv Meningococcal serogroups and surveillance: a systematic review and survey
title Meningococcal serogroups and surveillance: a systematic review and survey
spellingShingle Meningococcal serogroups and surveillance: a systematic review and survey
Peterson, Meagan E
Global Health
Humans
Meningococcal Infections
Meningococcal Vaccines
Neisseria meningitidis
Serogroup
title_short Meningococcal serogroups and surveillance: a systematic review and survey
title_full Meningococcal serogroups and surveillance: a systematic review and survey
title_fullStr Meningococcal serogroups and surveillance: a systematic review and survey
title_full_unstemmed Meningococcal serogroups and surveillance: a systematic review and survey
title_sort Meningococcal serogroups and surveillance: a systematic review and survey
dc.creator.none.fl_str_mv Peterson, Meagan E
Li, You
Bita, André
Moureau, Annick
Nair, Harish
Kyaw, Moe H
Abad, Raquel
Bailey, Freddie
de la Fuente Garcia, Isabel
Decheva, Antoaneta
Krizova, Pavla
Melillo, Tanya
Skoczyńska, Anna
Vladimirova, Nadezhda
author Peterson, Meagan E
author_facet Peterson, Meagan E
Li, You
Bita, André
Moureau, Annick
Nair, Harish
Kyaw, Moe H
Abad, Raquel
Bailey, Freddie
de la Fuente Garcia, Isabel
Decheva, Antoaneta
Krizova, Pavla
Melillo, Tanya
Skoczyńska, Anna
Vladimirova, Nadezhda
author_role author
author2 Li, You
Bita, André
Moureau, Annick
Nair, Harish
Kyaw, Moe H
Abad, Raquel
Bailey, Freddie
de la Fuente Garcia, Isabel
Decheva, Antoaneta
Krizova, Pavla
Melillo, Tanya
Skoczyńska, Anna
Vladimirova, Nadezhda
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv The China Scholarship Councile
Sanofi
Institut Pasteur
dc.subject.none.fl_str_mv Global Health
Humans
Meningococcal Infections
Meningococcal Vaccines
Neisseria meningitidis
Serogroup
topic Global Health
Humans
Meningococcal Infections
Meningococcal Vaccines
Neisseria meningitidis
Serogroup
description Background: Meningococcal disease continues to be a global public health concern due to its epidemic potential, severity, and sequelae. The global epidemiological data on circulating meningococcal serogroups have never been reviewed concurrently with the laboratory capacity for meningococcal surveillance at the national level. We, therefore, aimed to conduct a country-level review of meningococcal surveillance, serogroup distribution, and vaccine use. Methods: We conducted a systematic literature review across six databases to identify studies (published January 1, 2010 to October 16, 2017) and grey literature reporting meningococcal serogroup data for the years 2010-2016. We performed independent random effects meta-analyses for serogroups A, B, C, W, X, Y, and other. We developed and circulated a questionnaire-based survey to surveillance focal points in countries (N = 95) with known regional bacterial meningitis surveillance programs to assess their surveillance capacity and summarized using descriptive methods. Results: We included 173 studies from 59 countries in the final analysis. The distribution of meningococcal serogroups differed markedly between countries and regions. Meningococcal serogroups C and W accounted for substantial proportions of meningococcal disease in most of Africa and Latin America. Serogroup B was the predominant cause of meningococcal disease in many locations in Europe, the Americas, and the Western Pacific. Serogroup Y also caused many cases of meningococcal disease in these regions, particularly in Nordic countries. Survey responses were received from 51 countries. All countries reported the ability to confirm the pathogen in-country, while approximately 30% either relied on reference laboratories for serogrouping (N = 10) or did not serogroup specimens (N = 5). Approximately half of countries did not utilize active laboratory-based surveillance system (N = 22). Nationwide use of a meningococcal vaccine varied, but most countries (N = 36) utilized a meningococcal vaccine at least for certain high-risk population groups, in private care, or during outbreaks. Conclusions: Due to the large geographical variations in circulating meningococcal serogroups, each country should continue to be monitored for changes in major disease-causing serogroups in order to inform vaccine and control policies. Similarly, laboratory capacity should be appropriately scaled up to more accurately understand local epidemiology and disease burden, as well as the impact of vaccination programs.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-04-29
2019
2019-06-01
2019
2019-06-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/7530
url http://hdl.handle.net/20.500.12105/7530
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución-NoComercial-CompartirIgual 4.0 Internacional
http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución-NoComercial-CompartirIgual 4.0 Internacional
http://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Edinburgh University Press
publisher.none.fl_str_mv Edinburgh University Press
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416705963327488
score 15,811543

Similares en LA Referencia